APA

Blackney M., Kelly M., Zeidman R., Andreykiv M. & Plich A. (20160610). The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Chicago

Blackney M, Kelly M, Zeidman R, Andreykiv M and Plich A. 20160610. The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Harvard

Blackney M., Kelly M., Zeidman R., Andreykiv M. and Plich A. (20160610). The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

MLA

Blackney M, Kelly M, Zeidman R, Andreykiv M and Plich A. The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20160610.